Pfizer and Viatris Healthcare South Africa (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the increased risk of meningioma associated with prolonged use....
Novartis, during its portfolio review (Tegretol S® oral suspension included) observed the possibility of exceeding defined permitted daily exposure (PDE) when the product is taken above 1200 mg/day in adult patients because of the quantity of sorbitol in the formulation. Sorbitol is one of the...
The DHCP letter is intended to inform healthcare professionals about the risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines. Pseudoephedrine-containing medicines are contraindicated in patients with severe or uncontrolled hypertension, or with severe acute or...
The DHCP letter is intended to inform healthcare professionals about the risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines. Pseudoephedrine-containing medicines are contraindicated in patients with severe or uncontrolled hypertension, or with severe acute or...
GlaxoSmithKline (GSK) South Africa, in collaboration with SAHPRA, would like to inform healthcare professionals about the risk of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of aciclovir and valaciclovir-containing medicines....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Dr. Reddy’s Laboratories (Pty) Ltd would like to draw your attention to the recommended calculations of contraception duration after completion of therapy with genotoxic anticancer medicines (including potential genotoxic metabolites)....
Eisai Pharmaceuticals Africa (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the recommended calculations of contraception duration after completion of therapy with Halaven® (eribulin mesylate), including its potential genotoxic metabolites....
PharmaDynamics and other collaborators, would like to warn healthcare professionals about the risk of intrathecal administration of intravenous (IV) tranexamic acid, which may result in serious lifethreatening injuries, including seizures, cardiac arrhythmias, paraplegia, permanent neurological injury, and death. There have been reports of IV tranexamic...
Acino Pharma (Pty) Ltd, Adcock Ingram Limited, Aspen Pharmacare, Cipla Medpro, Ranbaxy Pharmaceuticals (Pty) Ltd and Pharmaceutical Contractors (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to draw your attention to the risk of posterior reversible encephalopathy syndrome...
The DHCP letter initiated by Roche is intended to inform healthcare professionals about deregistration of approved indications for Gavreto® (pralsetinib) and removal from the South African pharmaceutical market....